TMS Co., Ltd. (JP:4891) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TMS Co., Ltd. has secured a U.S. patent for a new treatment for acute kidney injury using compounds including TMS-008, further strengthening its global intellectual property portfolio alongside recent grants in Japan and China. This development highlights TMS’s commitment to advancing innovative treatments in areas with high unmet medical needs.
For further insights into JP:4891 stock, check out TipRanks’ Stock Analysis page.